Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective multicenter real-world study of IGE025 in Chinese children with allergic asthma
CTR20202226Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in allergic asthma, sponsored by Novartis. Started Nov 2020; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on CTR20202226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202226.